SynthesisMolecular psychiatry2026
Brain structural abnormalities in treatment-resistant schizophrenia.
Synthesis in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal brain structural changes during clozapine treatment: associations with neuroreceptor architecture and clinical response.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
Treatment-resistant schizophrenia (TRS) poses a considerable challenge in psychiatric care, with approximately 10-60% of patients exhibiting non-responsiveness to antipsychotic medication. While early treatment could improve clinical outcomes, the absence of objective biomarkers hinders timely intervention. General structural changes have been suggestively associated with TRS. However, there is a lack of clear and robust conclusions due to challenges in obtaining data from TRS cases with large sample sizes. To address this knowledge gap, we collaborated with Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) consortium to investigate brain structural changes associated with TRS. Leveraging data from multiple institutions spanning various continents and ethnic groups, our meta- and mega-analysis revealed a significant reduction in the volume of bilateral putamen and bilateral hippocampus, as well as the left superior frontal gyrus (SFG) surface area in TRS patients compared with non-TRS patients with sufficient statistical power. Further analysis, incorporating data from healthy controls (HCs), unveiled a decreasing trend in bilateral hippocampal volumes and left SFG surface area from HCs to non-TRS patients and further to TRS patients. There were no significant effects of either clozapine dose or cumulative antipsychotic exposure on bilateral hippocampal volumes or left SFG surface area. In contrast, the putamen volume exhibited an increase in non-TRS patients compared with HCs, with no significant difference between TRS patients and HCs. Antipsychotic exposure was significantly correlated with the putamen volume with small effect size. In conclusion, this study underscores the volume of the hippocampus and SFG as potential biomarkers for TRS.
Indexed as
Identifiers
41904268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.